bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure Legends from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

Supplementary Figure 1: Receiver operation characteristic (ROC) curve analysis was employed to determine the cutoff score for the high expression of miR-374b. Supplementary Figure 2ï¼šDepletion of miR-374b promoted cell proliferation and suppressed serum starvation-induced apoptosis in T-LBL cells. Supplementary Figure 3: The effect of Replenishment of Wnt16b and AKT1 on cell growth and apoptosis in SUP-T1-374b cells. Supplementary Figure 4: miR-374b and AKT inhibitor V inhibit the AKT phosphorylation and suppress cell growth as well as enhance cell apoptosis. Supplementary Figure 5ï¼šThe effect of Î²-catenin on the roles of miR-374b in T-LBL cells. Supplementary Figure 6: Inhibition of PTEN enhanced the activation of AKT and rescued the effect of miR-374b on cell proliferation and cell apoptosis.
Supplementary Figure 5 from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Presence of NRAS Mutations or Copy Number Gain is Associated with Overall Survival Across the Oncopanel Cohort (n=109).
Supplemental Figure 3 from NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Authors: Huang Junwei , Zhou Yi , Thomas Gregory S. , Gu Zhimin , Yang Ye , Xu Hongwei , Tricot Guido , Zhan Fenghuang
Published: April 2023

Supplemental Figure 3. Proliferation and viability in a p53-expressing MM cell line. A, Immuno blot for p53 and CKS1B in parental and CKS1B-overexpressing MM cell lines. B, Proliferation of parental and CKS1B-overexpressing MM cell lines upon mock treatment, treatment with MLN4924, or treatment with one of three concentrations of bortezomib. C, Titrated viability of parental and CKS1B-overexpressing MM cell lines upon treatment with different concentrations of MLN4924.
Figure S5 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S5. SK1-I did not enhance doxorubicin sensitivity in KJDSV40 cells in vitro.
Supplementary Figure 1 and 2 from A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Authors: Robbins Paul F. , Kassim Sadik H. , Tran Thai L.N. , Crystal Jessica S. , Morgan Richard A. , Feldman Steven A. , Yang James C. , Dudley Mark E. , Wunderlich John R. , Sherry Richard M. , Kammula Udai S. , Hughes Marybeth S. , Restifo Nicholas P. , Raffeld Mark , Lee Chyi-Chia R. , Li Yong F. , El-Gamil Mona , Rosenberg Steven A.
Published: April 2023

Supplementary Figure 1 and 2. Supplementary Figure 1. Evaluation of persistence and function of TCR-transduced T cells following adoptive transfer in responding and non-responding patients. Supplementary Figure 2. Evaluation of function of TCR-transduced T cells in vaccinated and unvaccinated patients.
Figure S2 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S2. Adenovirus infection of murine keratinocytes does not alter normal cell responses.
Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Authors: Kang Min H. , Wang Jing , Makena Monish R. , Lee Joo-Sang , Paz Nancy , Hall Connor P. , Song Michael M. , Calderon Ruben I. , Cruz Riza E. , Hindle Ashly , Ko Winford , Fitzgerald Jonathan B. , Drummond Daryl C. , Triche Timothy J. , Reynolds C. Patrick
Published: April 2023

Supplementary Figure 3: Representative pictures of macrophage infiltration in tumors.
Supplemental Figure 2 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Authors: Kang Min H. , Wang Jing , Makena Monish R. , Lee Joo-Sang , Paz Nancy , Hall Connor P. , Song Michael M. , Calderon Ruben I. , Cruz Riza E. , Hindle Ashly , Ko Winford , Fitzgerald Jonathan B. , Drummond Daryl C. , Triche Timothy J. , Reynolds C. Patrick
Published: April 2023

Supplementary Figure 2: The effect of plasma caroxylesterase activity on the conversion of CPT-11 to SN-38 in mouse and human plasma.
Supplemental Fig. 2 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Authors: Cui Di , Dai Jinlu , Keller Jill M. , Mizokami Atsushi , Xia Shujie , Keller Evan T.
Published: April 2023

Supplemental Figure 2. PF-03084014 combined with docetaxel suppresses tumor cell proliferation, induces apoptosis and inhibits tumor angiogenesis in mice.
Supplementary Table S2 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Table S2. The 71 microRNAs expressed in at least 75% of the samples in the training cohort
Supplemental Figure 3 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure 3. AR full length was highly expressed in nucleus of ENZ-R compared to CR LNCaP xenograft tumors.
Supplementary Figure S3 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S3. The effects of PF-05212384 on the phosphorylation of the PI3K/mTOR downstream targets S6 and 4EBP1 as a function of PF-05212384 (10 μM) treatment time following irradiation (7.5 Gy) for exponentially growing A) UMSCC1 and B) UMSCC46 HNSCC cells.
Supplementary Table S2 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Table S2: Cell cycle dual blockade experiments. (A) Cell cycle: Quantitative analysis of proportion of cells in G1, S and G2/M phases, calculated as mean +/- SEM of 3 experiments (at 24 hours). Average CV is provided: a CV <5% is acceptable for cell cycle analysis. (B) Apoptosis assay, average total apoptosis + necrosis by flow cytometry, expressed as a percentage of total cells; mean of 5 experiments with SEM. NT: untreated; E10: erlotinib 10 ÂµM; A1: AEW541 1 ÂµM; B5: BYL719 5 ÂµM.
Supplementary Materials and Legends from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Supplementary Materials and Legends
Table S3 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Table S3. Molecular characteristics of colorectal cancer cell lines and PDX (VHIO panel)
Supplementary figure legends from Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Authors: Liu Yan , Hawkins Oriana E. , Vilgelm Anna E. , Pawlikowski Jeffrey S. , Ecsedy Jeffrey A. , Sosman Jeffrey A. , Kelley Mark C. , Richmond Ann
Published: April 2023

Supplementary figure legends
Supplementary Table S2 from Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Authors: Strekalova Elena , Malin Dmitry , Good David M. , Cryns Vincent L.
Published: April 2023

Supplementary Table S2. Identification of proteins differentially expressed in response to methionine deprivation.
Supplementary Figures from Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)
Authors: Magbanua Mark Jesus M. , Rugo Hope S. , Wolf Denise M. , Hauranieh Louai , Roy Ritu , Pendyala Praveen , Sosa Eduardo V. , Scott Janet H. , Lee Jin Sun , Pitcher Brandelyn , Hyslop Terry , Barry William T. , Isakoff Steven J. , Dickler Maura , van't Veer Laura , Park John W.
Published: April 2023

Supplementary Figure 1. Development, optimization and performance of the gene expression assay. Supplementary Figure 2. Evaluation of assay performance using cancer cell line spike-in models. Supplementary Figure 3. Sample processing and quality control measures Supplementary Figure 4. Expression analysis of CTCs and matched normal blood samples. Supplementary Figure 5. Subtype and proliferation status. Supplementary Figure 6. Serial analysis. Supplementary Figure 7. Clustering analysis of copy number data. Supplementary Figure 8. ESR1 and ERBB2 status in CTCs and patient outcome Supplementary Figure 9. CTC molecular subtype and patient outcome.
File S2 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Qiu Fuman , Yang Lei , Ling Xiaoxuan , Yang Rongrong , Yang Xiaorong , Zhang Lisha , Fang Wenxiang , Xie Chenli , Huang Dongsheng , Zhou Yifeng , Lu Jiachun
Published: April 2023

File S2. Validation of those differentially expressed genes between A549-miRNA-499-T and A549-miRNA-499-C cells by the quantitative real-time PCR method.
Supplemental Methods from Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Authors: Brechbuhl Heather M. , Finlay-Schultz Jessica , Yamamoto Tomomi M. , Gillen Austin E. , Cittelly Diana M. , Tan Aik-Choon , Sams Sharon B. , Pillai Manoj M. , Elias Anthony D. , Robinson William A. , Sartorius Carol A. , Kabos Peter
Published: April 2023

Supplemental method section with increased detail regarding methods used in the manuscript.
Figure S2 from Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component
Authors: Avigdor Bracha Erlanger , Beierl Katie , Gocke Christopher D. , Zabransky Daniel J. , Cravero Karen , Kyker-Snowman Kelly , Button Berry , Chu David , Croessmann Sarah , Cochran Rory L. , Connolly Roisin M. , Park Ben H. , Wheelan Sarah J. , Cimino-Mathews Ashley
Published: April 2023

Supplemental figure S2
Supplementary Material from Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Authors: Sen Triparna , Tong Pan , Diao Lixia , Li Lerong , Fan Youhong , Hoff Jennifer , Heymach John V. , Wang Jing , Byers Lauren Averett
Published: April 2023

This file contains the supplementary figures and figure legends. Figure S1: WEE1 is overexpressed in small cell lung cancer (SCLC) compared with non-small cell lung cancer cell lines, and targeting WEE1 with AZD1775 prevents sub-G1 accumulation of WEE1 in AZD1775-sensitive cells. Figure S2: WEE1 inhibition is synergistic with temozolomide (TMZ) independent of initial sensitivity to WEE1 targeting in small cell lung cancer (SCLC) cell lines. Figure S3: Increased basal expression of members of the mTOR signaling pathway in small cell lung cancer cells showing primary resistance to AZD1775. Figure S4: Co-targeting AXL and mTOR overcomes de novo AZD1775 resistance in small cell lung cancer in vitro. Figure S5: Co-inhibition of AXL and/or mTOR pathway enhances the antitumor efficacy of WEE1 inhibition in small cell lung cancer in vivo. Figure S6: AXL/mTOR signaling activates other DNA repair proteins via the ERK/p90RSK pathway. Figure S7: Generation of models with acquired AZD1775 resistance. Supplementary Materials and Methods - Additional details of materials and methods used in this study like SCLC cell line authentication, targeted knockdown of WEE1 and AXL, PCR, cell viability aasay, cell cycle analysis, RPPA and immunofluorescence. Supplementary tables - Table S1: Genotypic status of human cell lines treated with the WEE1 inhibitor AZD1775. Table S2: Primer sequences for WEE1, AXL, and GAPDH. Table S3: List of primary antibodies.
Supplementary Table S4 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Combination of p-niclosamide and imatinib eliminated LSCs in vivo.
Supplementary Table S2 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Characteristics of patients with chronic myelogenous leukemia.
Supplemental Figure S5 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Figure S5: METABRIC Boxplot and survival figures
Figure S4 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

iNOS expression in macrophages with CSF1R c.1085 genotype A_A and A_G.
Supplementary Figure 4 from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

HSP90 surface expression on Breast Cancer Cell Lines
Supplementary Figures S1-S5 and Legends from AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
Authors: Jang Ji Eun , Eom Ju-In , Jeung Hoi-Kyung , Cheong June-Won , Lee Jung Yeon , Kim Jin Seok , Min Yoo Hong
Published: April 2023

Supplementary figure S1. Differential sensitivity of human AML LSCs to JQ1. Supplementary figure S2. Relative levels of the autophagy pathway effectors LC3-II, beclin-1, and pULK1 (S555). Supplementary figure S3. Autophagy induction in KG1 and KG1a cells and effects of autophagy inhibition on JQ1-induced apoptosis in LSCs. Supplementary figure S4. JQ1-induced apoptosis through intrinsic apoptosis pathway in JQ1-sensitive LSCs. Supplementary figure S5. Diagram illustrating the potential effects of the BET inhibitor JQ1 in JQ1-resistant LSCs.
Supplementary Tables from Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Authors: Torres-Adorno Angie M. , Lee Jangsoon , Kogawa Takahiro , Ordentlich Peter , Tripathy Debu , Lim Bora , Ueno Naoto T.
Published: April 2023

Supplementary Table S1. Breast cancer cell lines' molecular receptor status and TNBC subtype classification. Supplementary Table S2. Effect of entinostat on the expression of apoptosisrelated gene pathways.
Supplementary Table 2 from Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Authors: Calagua Carla , Russo Joshua , Sun Yue , Schaefer Rachel , Lis Rosina , Zhang Zhenwei , Mahoney Kathleen , Bubley Glenn J. , Loda Massimo , Taplin Mary-Ellen , Balk Steven P. , Ye Huihui
Published: April 2023

Clinicopathologic characteristics of hormone-naÃ¯ve PCa expressing PD-L1 in â‰¥25% of tumor cells.
Supplementary Figure 1 from Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients
Authors: Brand Judith S. , Hedayati Elham , Humphreys Keith , Ludvigsson Jonas F. , Johansson Anna L.V. , Bergh Jonas , Hall Per , Czene Kamila
Published: April 2023

Cumulative incidence of VTE by chemotherapy and FVL carriership, overall and stratified by age at diagnosis.
Contribution Form from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Conflict of Interest Form
Supplementary Figure S6 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

IGF2BP3 mRNA targets expression after treatment with JQ1
Figure S8 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 8. (A & B) OCI-AML3 cells transduced with Ctrl or PKCÎµ-expressing retroviruses were analyzed for (A) western blot or (B) cell growth every 2 days by MTS analysis. (C) Bar graph representing the number of colonies formed by CTRL or PKCÎµ-expressing mouse MLL-AF9 leukemia cells seeded at the indicated concentrations in methylcellulose. Data are represented as the mean {plus minus} SD of three technical replicates. (E & F) THP-1 cells were transduced with retroviral vectors that constitutively express PKCÎµ and GFP (PKCÎµ) or just GFP-expressing control (Ctrl) viruses. Four days after transduction, GFP+ cells were isolated by FACS and treated with 80ÂµM of (E) AA or (F) 200ÂµM TTFA. The percentage of Annexin V+ cells was evaluated 24 hours after treatment by flow cytometry. Data are represented as mean {plus minus} SD of three independent experiments. (G & H) U937 cells transduced with lentiviral vectors co-expressing GFP and either CTRL shRNA or PKCÎµ_1 shRNA. Four days after transduction, cells were treated with 100ÂµM of (G) AA or (H) 200ÂµM TTFA and then analyzed 24 hours later for the percentage of Annexin V+ cells by Flow Cytometry analysis. Data are represented as mean {plus minus} SD of three independent experiments. (*p{less than or equal to} 0.05; **p{less than or equal to}0.01).
Table S1 from Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients
Authors: Drögemöller Britt I. , Brooks Beth , Critchley Carol , Monzon José G. , Wright Galen E.B. , Liu Geoffrey , Renouf Daniel J. , Kollmannsberger Christian K. , Bedard Philippe L. , Hayden Michael R. , Gelmon Karen A. , Carleton Bruce C. , Ross Colin J.D.
Published: April 2023

Table S1 provides a summary of the genetic association results in the European only cohort
Supplementary Figure S3 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

Panel A and B show that treatment of PC-3 PCa cells with the PI3K inhibitor NVP-BEZ235 or the AKT inhibitor MK2206 downregulated expression of CYP11A1 and CYP17A1 mRNA. Panel C-G show the effect of RUNX2 knockdown, overexpression of constitutively active FOXO1 (FOXO1-A3), OCN knockdown, GPRC6A knockdown and ectopic expression of CREB on expression of CYP11A1 and CYP17A1 mRNA in PC-3 cells.
Supplementary Data from NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP
Authors: Lucena-Cacace Antonio , Otero-Albiol Daniel , Jiménez-García Manuel P. , Muñoz-Galvan Sandra , Carnero Amancio
Published: April 2023

Figure S1: Overall survival probability of the patients according to NAMPT levels segregated by colon cancer stage. Figure S2. Tumorigenic properties induces by NAMPT Figure S3. Effect of a second shRNA against NAMPT in the tumorigenic capability of tumor cells. Figure S4. CD133+ single cell derived tumorspheres of HCT116. Figure S5.Tumorigenic capabilities NAMPT-dependent in HCT 116 +/+ p53 wild type. Figure S6. (A) GSE34053 database, from human colon tumors, have transcription profiles of sorted CD133+ cells. We analyzed the correlation of CD133+ cells with NAMPT expression along with the following: HES1, OCT4 and SOX9. (B) GSE14774 database includes transcription profiles of a supplementary colon cancer cell line, HT-29, both in monolayer culture and tumorspheres. We analyzed the correlation of NAMPT on either monolayer or tumorspheres along with the following: HES1, OCT4 and SOX9. (C, left graph) Clonal heterogeneity analysis reveals that 1 mM NMN can rescue the number of holoclones up to vector levels in both cell lines. (C, right graph) Clonal heterogeneity analysis reveals that treatment with 60 ng/mL visfatin results in the same effect over holoclones. Figure S7. Effect of the addition of the NAMPT product NMN, or the extracellular NAMPT (visfatin) to HCT116 p53 WT cells depleted of NAMPT. Figure S8. (A) Clonal heterogeneity analysis reveals that 2.5 nM FK866 abruptly decreases the number of holoclones in both cell lines. (B) Clonal heterogeneity analysis reveals that 1 ÂµM sirtinol also abruptly decreases the number of holoclones. Figure S8C-I. Effect of the addition of the Sirt1 inhibitor Sirtinol to HCT116 p53 WT cells overexpressing NAMPT. Left half of the figure: we added 1 ÂµM sirtinol to cells overexpressing NAMPT (NAMPT+S, Â-�, orange bars) and compared different properties to parental expressing only vector (v, Â-�, grey bars), shRNA only (sh, O, white bars) or NAMPT overexpression only (NAMPT, Â- , black bars). (C) growth curve, (D) clonogenic assay, (E) CD133 percentage of cells, (F) number of tumorspheres, (G) Colony type, (H) stem cell pathway effectors and (I) EMT effectors [*, p<0.05; **, p<0.01; ***, p<0.001 compared to NAMPT overexpression only]. Figure S9. Effect of the addition of the NAMPT inhibitor (FK866) to HCT116 p53 WT cells overexpressing NAMPT. Table S1. Correlation analysis using GSE20916 of the prognosis predictive gene set driven by NAMPT. Here, we show correlations of each element with NAMPT. All data shown is highly significant (p<0.01).
Suppl. Figure 7 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Representative multicolor stainings of CFL1, CRKII, NME2, and CNTN1 on acetone-fixed cryosections with markers for common cell types in IDHmut LGGs: anti-GFAP (tumor cells, #Z0334, DAKO), anti-CD68 (microglia/ macrophages, #M0718, DAKO), anti-CD31 (endothelial cells, #223609, BD Pharmingen). Detection was performed by using fluorochrom-conjugated secondary antibodies (anti-mouse AF647 (#A-21463, Invitrogen), anti-rabbit AF555 (#A-21428, Invitrogen), DAPI (#D1306, ThermoFisher), and the Zenon AF488 mouse IgG1 Labeling Kit (#Z25001, ThermoFisher)) according to the manufacturer`s protocol (scale bar: 50 ÂµM, scale bar zoom: 10 ÂµM).
Suppl. Figure 4 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Gating strategy to identify cytokine-secreting cells by cytokine capture assay. The acquired cells were gated based on their size and granularity as lymphocytes excluding cell debris. Then we gated on single cells to remove cell duplexes and clusters. Apoptotic cells were gated out next by gating on pacific orange (PO)-negative cells (live cells). The respective T-cell (TC) population was identified by surface staining with anti-CD4 PerCP-Cy5.5, and anti-CD8-V450 antibodies. The cytokine-positive cell gate was placed according to a FMO control (exemplarily shown for IFN-ð�›¾) and the frequency of cytokine-secreted cells in samples stimulated with IgG1 peptide (negative control) or the antigen of interest (exemplarily shown for CFL1) were determined based on that gate.
supplementary Table S7 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Results of differential drug responses of BM1 and BM2 classified colorectal cell lines.
supplementary Figures from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Figure S1. Principal component analysis and hierarchical clustering of the 218 BRAF mutant patient cohort;Figure S2: Gene-wise and patient-wise biclustering heatmap of the 218 BRAF mutant patient cohort and comparison of BRAF mutant subtypes obtained with and without adjusting for microsatellite instability status;Figure S3: Geneset enrichment analysis (GSEA) of BM subtypes for the four most enriched signature of the Hallmark collection and gene overlap between signatures and BM-specific genes;Figure S4: Patient-level single sample geneset enrichment analysis (ssGSEA) between BM subtypes, double BRAF wild-type KRAS wild-type (WT2) and KRAS mutant patients for the hallmark signature collection;Figure S5: Patient-averaged single sample geneset enrichment analysis (ssGSEA) between BM subtypes, double BRAF wild-type KRAS wild-type (WT2) and KRAS mutant patients for the hallmark signature collection;Figure S6: Gene overlap between selected sets of gene signatures used in this study;Figure S7: Immune landscape of the BM subtypes;Figure S8: Methylation analysis of BM subtypes using TCGA data;Figure S9: Survival and clinical characteristics of the BRAF mutant patients enrolled in the survival analysis;Figure S10: Performance of the generalized model used to classify patients into BM1 and BM2 subtypes;Figure S11: Drug responses of colorectal cancer cell lines classified into BM1 and BM2.
Supplementary Table S4 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Full list of differentially expressed genes identified in comparison of the 10 HG bladder cancer urine samples to 3 LG bladder cancer urine samples based on urinary RNA-seq data in the urinary biomarker discovery.
Supplementary Table S2 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Supplementary Table S2; Characteristics of patients and their cysts in the discovery set.
Table S2 from Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Authors: Niu Xiaomin , Liu Fatao , Zhou Yi , Zhou Zhen , Zhou Daizhan , Wang Ting , Li Ziming , Ye Xiangyun , Yu Yongfeng , Weng Xiaoling , Zhang Hong , Ye Junyi , Liao Meilin , Liu Yun , Chen Zhiwei , Lu Shun
Published: April 2023

Sixty erlotinib-related aberrant DNA methylation genes in both patients discovered with the the methyl-sensitive cut counting sequencing (MSCC) screening method.
Supplementary Figures legends from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

Supplementary Figures legends
Figure S4 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

Fold change in MMPs 1 and 10 expression in HPV+ primary culture after 5-aza treatment, as determined by qRT-PCR
Figure S3 from Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Authors: Weberpals Johanne I. , Lo Bryan , Duciaume Marc M. , Spaans Johanna N. , Clancy Aisling A. , Dimitroulakos Jim , Goss Glenwood D. , Sekhon Harman S.
Published: April 2023

Multivariate analysis of HPV status and clinical data
Supplementary Table S2 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Genes that are significantly different between vorinostat and untreated cells with at least a four-fold difference in expression.
Supplementary Figure 2 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Examples of R2* time series (left column, R2* range 40 s-1) and corresponding power frequency spectra (R2* power range displayed: 0 - 30) for voxels within CALR HNSCC xenografts classified as significantly fluctuating (CALR tumor - top two rows) and without significant fluctuations (CALR tumor - middle two rows, adjacent muscle - bottom row).
Supplemental Table I from Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Authors: Zhu Xuguang , Enomoto Keisuke , Zhao Li , Zhu Yuelin J. , Willingham Mark C. , Meltzer Paul , Qi Jun , Cheng Sheue-yann
Published: April 2023

Frequency of pathological changes
Supplementary Table S3 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Table S3. List of the Pearson correlation coefficients between the two peptides of each protein.
Supplemental Data from XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Authors: Ranganathan Parvathi , Kashyap Trinayan , Yu Xueyan , Meng Xiaomei , Lai Tzung-Huei , McNeil Betina , Bhatnagar Bhavana , Shacham Sharon , Kauffman Michael , Dorrance Adrienne M. , Blum William , Sampath Deepa , Landesman Yosef , Garzon Ramiro
Published: April 2023

Table S1: IC50 values of Topo IIa inhibitors (idarubicin, etoposide, mitoxantrone, daunorubicin) and selinexor at 48hrs as measured by WST-1 assay for AML cell lines MV4-11 and MOLM-13. Table S2: Combinatorial Index (CI) values of concomitant treatment of selinexor with Topo IIa inhibitors (idarubicin and daunorubicin) in AML cell lines MV4-11 and MOLM-13. Table S3: Combinatorial Index (CI) values of concomitant treatment of selinexor with Topo IIa inhibitors (idarubicin and daunorbicin) in AML patient blasts. Table S4: Combinatorial Index (CI) values of concomitant treatment of selinexor with individual Topo IIa inhibitors (etoposide, mitoxantrone) in AML cell lines MV4-11 and MOLM-13. Table S1: IC50 values of Topo IIα inhibitors and selinexor in AML cell lines Table S2: Combinatorial Index (CI) values of selinexor with idarubicin and daunorubicin in AML cell lines Table S3: Combinatorial Index (CI) values of selinexor with idarubicin/daunorubicin in AML patient cells Table S4: Combinatorial Index (CI) values of selinexor with Topo IIα inhibitors (etoposide and mitoxantrone) with selinexor in AML cell lines
Supplementary Fig 11 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 11
Supplementary Figure 2 from Radiotherapy for Non–Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues
Authors: Siva Shankar , Lobachevsky Pavel , MacManus Michael P. , Kron Tomas , Möller Andreas , Lobb Richard J. , Ventura Jessica , Best Nickala , Smith Jai , Ball David , Martin Olga A.
Published: April 2023

Mean (+/- SD) Changes in concentration of plasma cytokine levels at baseline, 1-hour, 24-hours and 4-weeks after commencement of RT stratified by use of concurrent chemotherapy. Change at 1-hour in MDC and 4 weeks in MIP-1α is marked with an asterisk.
Supplemental legend from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Authors: Karnes R. Jeffrey , Sharma Vidit , Choeurng Voleak , Ashab Hussam Al-Deen , Erho Nicholas , Alshalalfa Mohammed , Trock Bruce , Ross Ashley , Yousefi Kasra , Tsai Harrison , Zhao Shuang G. , Tosoian Jeffrey J. , Haddad Zaid , Takhar Mandeep , Chang S. Laura , Spratt Daniel E. , Abdollah Firas , Jenkins Robert B. , Klein Eric A. , Nguyen Paul L. , Dicker Adam P. , Den Robert B. , Davicioni Elai , Feng Felix Y. , Lotan Tamara L. , Schaeffer Edward M.
Published: April 2023

Supplemental legend
Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Authors: Shah Manish A. , Starodub Alexander , Sharma Sunil , Berlin Jordan , Patel Manish , Wainberg Zev A. , Chaves Jorge , Gordon Michael , Windsor Kevin , Brachmann Carrie Baker , Huang Xi , Vosganian Greg , Maltzman Julia D. , Smith Victoria , Silverman Jeffrey A. , Lenz Heinz-Josef , Bendell Johanna C.
Published: April 2023

Method for Free and Total MMP9 assays
Figure S5 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

Integrated analysis of prognostic genes of SOC
Figure S3 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

NMF clustering For HGSOC and LGSOC separately
Supplementary Figure S3: Effect of ipilimumab on FOXP3+ cells in human tumors from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

The representative IHC micrographs for FOXP3+ cells from stage-matched untreated and Ipi-treated metastatic melanoma, bladder and prostate tumors at 10X and 20X magnifications (inset).
Supplementary Figure 4 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Immunofluorescent staining of MDSCs in HM-1 tumors
Supplemental Table S3. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Patient Characteristics by Response
Supplemental Table S2. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Gene Expression Signatures
Supplementary Table 3 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

The Primary Antibodies Used for Immunohistochemistry Studies
Data Supplement from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Supplementary materials and methods
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response
Authors: Chatterjee Shilpak , Chakraborty Paramita , Daenthanasanmak Anusara , Iamsawat Supinya , Andrejeva Gabriela , Luevano Libia A. , Wolf Melissa , Baliga Uday , Krieg Carsten , Beeson Craig C. , Mehrotra Meenal , Hill Elizabeth G. , Rathmell Jeffery C. , Yu Xue-Zhong , Kraft Andrew S. , Mehrotra Shikhar
Published: April 2023

Supplementary Figures and Figure Legends
Table S1 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Lab IHC
Figure S5 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Carbo vs talazoparib
Figure S2 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Histology
Figure S1 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

HER2 FISH BCX.017
Supplementary Figure 1 and 2 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

Figure S1: Evidence of FGFR1 heterogeneity by FISH in samples from the same patient. FGFR1 FISH images from Patient 4 (A) and patient untreated on the study (B, Patient X) are shown. Patient 4's samples were both taken from the lung, with one showing amplification and the other showing polysomy. Patient X's samples were taken from a soft tissue lesion and the lung, with the former showing gene amplification and the latter, 2-3 copies per cell without amplification. Figure S2: C2D1 and C3D1 PK data with reference to response
Supplementary Figure 2. from Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
Authors: Osswald Matthias , Blaes Jonas , Liao Yunxiang , Solecki Gergely , Gömmel Miriam , Berghoff Anna S. , Salphati Laurent , Wallin Jeffrey J. , Phillips Heidi S. , Wick Wolfgang , Winkler Frank
Published: April 2023

A, In permeable (red line) vs. non-permeable (green line) brain metastases, the extravasation of sodium fluorescein was significantly different directly after i.v. sodium fluorescein injection, and at the end of the corresponding time series (n=7 permeable metastases from n=6 animals, n=16 non-permeable metastases from n=12 animals; ***p<0.001, Mann-Whitney Rank Sum tests; error bars show standard errors). Dotted line shows the chosen cut-off for the classification in permeable vs. non-permeable metastases. B, Regression analysis between metastasis growth (growth rate per day in percentage) and blood-brain-barrier permeability (permeability index); pearsons coefficient R= 0.6, p=0.002, Analysis of Variance. Dotted line shows the chosen cut-off for the classification in permeable vs. non-permeable metastases. C, Growth of one very large (>20.000 tumor cells, in red) and permeable (permeability measurement not shown) brain metastasis over one week, showing formation of new blood vessels over time (true angiogenesis); stitches of tilescans (D21 and D25); 3D reconstruction of z-stacks of 237-540Ã‚Âµm; scale bars 200Ã‚Âµm. All analyses were performed with in vivo data.
Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure 2
Supplementary Figures from Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Authors: Zhai Lijie , Ladomersky Erik , Lauing Kristen L. , Wu Meijing , Genet Matthew , Gritsina Galina , Győrffy Balázs , Brastianos Priscilla K. , Binder David C. , Sosman Jeffrey A. , Giles Francis J. , James Charles D. , Horbinski Craig , Stupp Roger , Wainwright Derek A.
Published: April 2023

Description of Supplementary Figures 1-9 that support the expression and clinical relevance of IDO1 in human GBM.